Metastatic HER2-amplified non-small-cell lung cancer treated with trastuzumab deruxtecan

被引：3
作者：
Yun, Karen M. [1 ]
Bazhenova, Lyudmila [1 ]
机构：
[1] UC San Diego Hlth, Div Hematol Oncol, Moores Canc Ctr, La Jolla, CA 92122 USA
来源：
BMJ CASE REPORTS | 2023年 / 16卷 / 05期
关键词：
Lung cancer (oncology); Therapeutic indications; IN-SITU HYBRIDIZATION; GENE AMPLIFICATION; HER2; GENE; IMMUNOHISTOCHEMISTRY; EXPRESSION; HER-2/NEU; SURVIVAL; MUTATION;
D O I：
10.1136/bcr-2022-253260
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Human epidermal growth factor receptor 2 (HER2) alterations can occur as gene mutations, gene amplification or protein overexpression. DESTINY-Lung01 and DESTINY-Lung02 demonstrated the efficacy of trastuzumab deruxtecan in the subsequent line setting in patients with unresectable or metastatic HER2-mutated non-small-cell lung cancer (NSCLC). Trastuzumab deruxtecan has not been studied in select patients with HER2-amplified NSCLC. Here, we present the first reported case of metastatic HER2-amplified NSCLC treated with trastuzumab deruxtecan with a durable response to therapy.
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Trastuzumab and Emerging Targeted Therapies for HER2-Amplified Early-Stage Breast Cancer
    Gajria, Devika
    ONCOLOGY-NEW YORK, 2009, 23 (11): : 28 - 35
  • [32] The Prognostic Significance of HER2 Overexpression in Non-small Cell Lung Cancer
    Takenaka, Masaru
    Hanagiri, Takeshi
    Shinohara, Shinji
    Kuwata, Taiji
    Chikaishi, Yasuhiro
    Oka, Soich
    Shigematsu, Yoshiki
    Nagata, Yoshika
    Shimokawa, Hidehiko
    Nakagawa, Makoto
    Uramoto, Hidetaka
    So, Tomoko
    Tanaka, Fumihiro
    ANTICANCER RESEARCH, 2011, 31 (12) : 4631 - 4636
  • [33] Mutational Subtypes and Prognosis of Non-Small-Cell Lung Cancer Harboring HER2 Mutations
    Xu, C.
    Wang, W.
    Zhuang, W.
    Huang, Z.
    Song, Z.
    Chen, Y.
    Liu, W.
    Chen, R.
    Guan, Y.
    Yi, X.
    Chen, G.
    Fang, M.
    Lv, T.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1940 - S1940
  • [34] Expression and association of HER2 with prognosis in early-stage (T1-T2N0M0) non-small cell lung cancer
    Xia, Qing
    Zhu, Zhihua
    Wang, Jian
    Situ, Dongrong
    Zhou, Ningning
    Jang, Wenqi
    TUMOR BIOLOGY, 2012, 33 (05) : 1719 - 1725
  • [35] Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer
    Hirsch, F. R.
    Varella-Garcia, M.
    Cappuzzo, F.
    ONCOGENE, 2009, 28 : S32 - S37
  • [36] Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer
    Cai, Qi
    You, Shuhui
    Huang, Jinglong
    Gong, Caifeng
    Zhang, Wen
    Zhou, Aiping
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
  • [37] Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab
    Lee, Hee Jin
    Kim, Joo Young
    Park, So Yeon
    Park, In Ah
    Song, In Hye
    Yu, Jong Han
    Ahn, Jin-Hee
    Gong, Gyungyub
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2015, 144 (04) : 570 - 578
  • [38] Spotlight on Trastuzumab Deruxtecan (DS-8201, T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
    Azar, Ibrahim
    Alkassis, Samer
    Fukui, Jami
    Alsawah, Fares
    Fedak, Kalub
    Al Hallak, Mohammed Najeeb
    Sukari, Ammar
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 103 - 114
  • [39] Surgery for metastatic pleural extension of non-small-cell lung cancer
    Mordant, Pierre
    Arame, Alex
    Foucault, Christophe
    Dujon, Antoine
    Barthes, Francoise Le Pimpec
    Riquet, Marc
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2011, 40 (06) : 1444 - 1449
  • [40] Downregulation of EIF4A2 in Non-Small-Cell Lung Cancer Associates with Poor Prognosis
    Xi Shaoyan
    Yong Juanjuan
    Tao Yalan
    He Ping
    Liang Jianzhong
    Wu Qinian
    CLINICAL LUNG CANCER, 2013, 14 (06) : 658 - 665
12345